The therapeutic strategies currently available for neurodegenerative diseases such as
Parkinson's disease target only the symptoms of the disease. Parkinson's disease, dementia …

Parkinson's disease (PD) is a neurodegenerative pathology, the origin of which is
associated with the death of neuronal cells involved in the production of dopamine. The …

Aging is the biggest risk factor for developing Parkinson's disease (PD), the second most
common neurodegenerative disorder. Several animal models have been developed to …

Pathogenic alpha-synuclein (asyn) aggregates are a defining feature of neurodegenerative
synucleinopathies, which include Parkinson's disease, Lewy body dementia, pure …

Abstract α-Synuclein (α-syn) accumulates as insoluble amyloid but also forms soluble α-syn
oligomers (αSOs), thought to be even more cytotoxic than fibrils. To detect and block the …

Aims Accumulation and propagation of pathological α‐synuclein (α‐Syn) are the major
contributing factors to the pathogenesis of Parkinson's disease (PD). Therapy to halt the …

Parkinson's Disease (PD) is strongly linked to the aggregation of the protein α-synuclein (α-
syn), an intrinsically disordered protein. However, strategies to combat PD by targeting the …

Neurodegenerative diseases (NDDs) are characterized by the progressive degeneration
and/or loss of neurons belonging to the central nervous system, and represent one of the …

The introduction of personalized medicine, through the increasing multi-omics
characterization of disease, brings new challenges to disease modeling. The scope of this …

Alzheimer's disease (AD) and Parkinson's disease (PD) are leading neurodegenerative
disorders marked by protein aggregation, with AD featuring amyloid-beta (Aβ) and tau …